Endosopy AI | Eliminating blind spots | Global Distribution

Executive Summary: Endovision

Standardizing Endoscopy Quality Control via Foundation AI

Investment Opportunity

Endovision is a Hong Kong-based MedTech startup solving the #1 challenge in upper-GI endoscopy: clinical blind spots. While competitors focus on commoditized polyp detection, Endovision provides a brand-agnostic software layer for real-time Quality Control (CAQ). Secured by a global distribution partnership with Medtronic and Cosmo Pharma, we are positioned as the essential software foundation for the next generation of endoscopy.

The Clinical Challenge: The "Blind Spot" Risk

• Manual Inefficiency: Manual EGD examinations routinely miss 22.5% of the mucosal surface due to operator cognitive and physical blind spots.

• Late Detection Mortality: Missed diagnoses plummet survival rates from 95% to 6% at late stages.

The Solution: Foundation, Not Replacement

Our AI acts as a "second set of eyes," enforcing systematic quality control without disrupting clinical workflows.

• Brand-Agnostic Core: Integrates with Olympus, Fujifilm, and Pentax systems via standard connection, serving as a neutral ecosystem hub.

• Proprietary Data Moat: Built on a 30,000+ patient data asset—10x–20x larger than typical competitors.

Commercial Strategy & Traction

• Global Scale: Leveraging Medtronic’s 2,000+ existing GI-Genius install base for rapid EU expansion.

• Regulatory First-Mover: CE/MDR Class IIa SaMD approval secured; FDA fast-track in progress (Expected Q2 2028).

• Business Model: Recurring SaaS revenue ($1,000/month per system) with tiered royalty structures.

The Ask: $1M Bridge Round (60% Committed)

We are closing our final bridge round to accelerate clinical validation and market entry.

• FDA Submission: Fast-tracking US market entry.

• EU Commercial Scaling: Technical support and market access for Medtronic pipeline.

• Pipeline Expansion: Finalizing EGC detection and auto-reporting modules.